731 related articles for article (PubMed ID: 27071815)
1. The gut microbiota and metabolic disease: current understanding and future perspectives.
Arora T; Bäckhed F
J Intern Med; 2016 Oct; 280(4):339-49. PubMed ID: 27071815
[TBL] [Abstract][Full Text] [Related]
2. Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk.
Miele L; Giorgio V; Alberelli MA; De Candia E; Gasbarrini A; Grieco A
Curr Cardiol Rep; 2015 Dec; 17(12):120. PubMed ID: 26497040
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of intestinal microbiota and microbial metabolites in metabolic control.
Herrema H; IJzerman RG; Nieuwdorp M
Diabetologia; 2017 Apr; 60(4):613-617. PubMed ID: 28013341
[TBL] [Abstract][Full Text] [Related]
4. Linking Microbiota to Human Diseases: A Systems Biology Perspective.
Wu H; Tremaroli V; Bäckhed F
Trends Endocrinol Metab; 2015 Dec; 26(12):758-770. PubMed ID: 26555600
[TBL] [Abstract][Full Text] [Related]
5. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities.
Brunkwall L; Orho-Melander M
Diabetologia; 2017 Jun; 60(6):943-951. PubMed ID: 28434033
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiological role of host microbiota in the development of obesity.
Kobyliak N; Virchenko O; Falalyeyeva T
Nutr J; 2016 Apr; 15():43. PubMed ID: 27105827
[TBL] [Abstract][Full Text] [Related]
7. Diet, gut microbiota and cognition.
Proctor C; Thiennimitr P; Chattipakorn N; Chattipakorn SC
Metab Brain Dis; 2017 Feb; 32(1):1-17. PubMed ID: 27709426
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota, diet, and obesity-related disorders-The good, the bad, and the future challenges.
Portune KJ; Benítez-Páez A; Del Pulgar EM; Cerrudo V; Sanz Y
Mol Nutr Food Res; 2017 Jan; 61(1):. PubMed ID: 27287778
[TBL] [Abstract][Full Text] [Related]
9. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
Halmos T; Suba I
Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
[TBL] [Abstract][Full Text] [Related]
10. The interaction between microbiome and host central nervous system: the gut-brain axis as a potential new therapeutic target in the treatment of obesity and cardiometabolic disease.
Wijdeveld M; Nieuwdorp M; IJzerman R
Expert Opin Ther Targets; 2020 Jul; 24(7):639-653. PubMed ID: 32441559
[TBL] [Abstract][Full Text] [Related]
11. [Gut microbiota and immune crosstalk in metabolic disease].
Burcelin R
Biol Aujourdhui; 2017; 211(1):1-18. PubMed ID: 28682223
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus.
Kootte RS; Vrieze A; Holleman F; Dallinga-Thie GM; Zoetendal EG; de Vos WM; Groen AK; Hoekstra JB; Stroes ES; Nieuwdorp M
Diabetes Obes Metab; 2012 Feb; 14(2):112-20. PubMed ID: 21812894
[TBL] [Abstract][Full Text] [Related]
13. Role of the Gut Microbiome in Obesity and Diabetes Mellitus.
Barlow GM; Yu A; Mathur R
Nutr Clin Pract; 2015 Dec; 30(6):787-97. PubMed ID: 26452391
[TBL] [Abstract][Full Text] [Related]
14. Gut Microbiota-Dependent Modulation of Energy Metabolism.
Heiss CN; Olofsson LE
J Innate Immun; 2018; 10(3):163-171. PubMed ID: 29131106
[TBL] [Abstract][Full Text] [Related]
15. Microbiota and Obesity.
Isolauri E
Nestle Nutr Inst Workshop Ser; 2017; 88():95-105. PubMed ID: 28346926
[TBL] [Abstract][Full Text] [Related]
16. Modulation of type 1 and type 2 diabetes risk by the intestinal microbiome.
Paun A; Danska JS
Pediatr Diabetes; 2016 Nov; 17(7):469-477. PubMed ID: 27484959
[TBL] [Abstract][Full Text] [Related]
17. Microbiota and metabolites in metabolic diseases.
Cani PD
Nat Rev Endocrinol; 2019 Feb; 15(2):69-70. PubMed ID: 30602737
[No Abstract] [Full Text] [Related]
18. Metabolism and Metabolic Disorders and the Microbiome: The Intestinal Microbiota Associated With Obesity, Lipid Metabolism, and Metabolic Health-Pathophysiology and Therapeutic Strategies.
Aron-Wisnewsky J; Warmbrunn MV; Nieuwdorp M; Clément K
Gastroenterology; 2021 Jan; 160(2):573-599. PubMed ID: 33253685
[TBL] [Abstract][Full Text] [Related]
19. 'The way to a man's heart is through his gut microbiota'--dietary pro- and prebiotics for the management of cardiovascular risk.
Tuohy KM; Fava F; Viola R
Proc Nutr Soc; 2014 May; 73(2):172-85. PubMed ID: 24495527
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission.
Cash JG; Konaniah E; Hegde N; Kuhel DG; Watanabe M; Romick-Rosendale L; Hui DY
Mol Metab; 2018 Oct; 16():55-64. PubMed ID: 30087032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
